Astrana Health (ASTH) to Release Quarterly Earnings on Thursday

Astrana Health (NASDAQ:ASTH - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of $0.28 per share and revenue of $628.11 million for the quarter. Astrana Health has set its FY 2025 guidance at EPS.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $665.21 million for the quarter, compared to analysts' expectations of $617.24 million. On average, analysts expect Astrana Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Astrana Health Price Performance

Shares of NASDAQ ASTH traded down $0.36 on Tuesday, hitting $32.03. The company's stock had a trading volume of 182,108 shares, compared to its average volume of 279,619. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a 50 day moving average of $30.57 and a 200-day moving average of $36.81. Astrana Health has a 12-month low of $23.12 and a 12-month high of $63.20. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of 24.64, a price-to-earnings-growth ratio of 1.37 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Barclays began coverage on Astrana Health in a research report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price target for the company. Truist Financial cut their target price on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Robert W. Baird decreased their price target on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Bank of America cut their price objective on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus decreased their target price on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Astrana Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.